Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as insulin lispro injection [rDNA origin] Low Mix, Insulin lispro mix 25
insulin lispro Low Mix · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 2 | ACTIVE_COMPARATOR | Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications. |
| 1 | ACTIVE_COMPARATOR | Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications. |
| Name | Type | Description |
|---|---|---|
| insulin lispro injection [rDNA origin] Low Mix | DRUG | - |
| Insulin lispro mix 25 | DRUG | Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications. |
| Glargine | DRUG | Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications. |
Inclusion Criteria: * Type 2 Diabetes * Already on Lilly insulin or beginning insulin therapy * 25 to 75 years old inclusive Exclusion Criteria: * Currently using, or had used during previous month, oral diabetes medication that is NOT approved for use in combination with insulin in patient's cou...
Insulin lispro Low Mix is used to treat Diabetes Mellitus Type 2. It is a fixed-ratio insulin product studied in adults with type 2 diabetes, including patients on twice-daily insulin regimens. Eli Lilly and Company is developing it, and the program has reached Phase 3 clinical development.
Insulin lispro Low Mix targets INSR, the insulin receptor, and acts as an agonist at that receptor. By activating the insulin receptor, the product is designed to support glucose lowering in people with type 2 diabetes. Its target class is receptor agonism, consistent with insulin-based therapy.
Eli Lilly and Company makes insulin lispro Low Mix. The company trades under the ticker LLY and is the developer of this fixed-ratio insulin lispro product for Diabetes Mellitus Type 2. The asset is in Phase 3 development.
Insulin lispro Low Mix is in Phase 3 development for Diabetes Mellitus Type 2. It is an investigational product and is not approved. Two Phase 3 trials have been completed, with no active trials currently listed, and total enrollment across those completed studies was 423 participants.
Two completed Phase 3 trials have studied insulin lispro Low Mix. NCT00551356 compared Lispro Mix 25 with glargine in type 2 diabetics in Mexico and enrolled 53 participants. NCT00231725 examined pen-related complaints in type 2 diabetics on twice-daily insulin across the United States, Spain, and the United Kingdom, enrolling 370 participants.
Yes. Insulin lispro Low Mix is also known as insulin lispro mix 25 and insulin lispro injection [rDNA origin] Low Mix. These names refer to the same fixed-ratio insulin lispro product developed by Eli Lilly and Company for Diabetes Mellitus Type 2. Searches for any of these names point to the same asset.